Enterome Bioscience, a France-based startup offering disease management solutions, has secured €10 million ($13.9m) in the first tranche of its series B round.
The round was led by Lundbeckfond Ventures, the corporate venturing subsidiary of pharmaceutical company Lundbeck, in conjunction with Natixis-backed venture firm Seventure Partners, both of which were existing investors. The round also saw participation from Omnes Capital.
Enterome Bioscience provides disease management solutions by recording, understanding and modifying the changes occurring in the gut microbiome. The gut microbiome is observed during disease and in response to therapeutic interventions, which opens up new arenas for modern day medicine and disease management.
Pierre Belichard, CEO of Enterome Bioscience said: “We are pleased that our existing investors have taken the decision to make a further financial commitment to Enterome. With these new funds we will be able make further significant progress towards our goal of developing new disease management solutions that will provide important benefits to patients suffering from conditions where the gut microbiome plays a key role.”
Enterome aims to utilise the funding to carry out key research and development, and business development activities pertaining to its proprietary Metagenotyping process. It previously raised $8.1m across two previous rounds.